D. Jong

Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study

D. D. de Jong, C. J. van der Woude, F. Hoentjen, 2020, BMJ Open.

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment

D. D. de Jong, C. J. van der Woude, F. Hoentjen, 2020, Alimentary pharmacology & therapeutics.